WILLIAM PEACOCK to Hemorrhage
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Hemorrhage.
Connection Strength
1.556
-
CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. Ann Emerg Med. 2017 May; 69(5):541-550.e1.
Score: 0.386
-
Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol. 2012 Dec; 35(12):730-7.
Score: 0.286
-
The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. Am J Emerg Med. 2020 06; 38(6):1163-1170.
Score: 0.120
-
A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. Curr Med Res Opin. 2017 09; 33(9):1717-1723.
Score: 0.101
-
Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. Am J Cardiol. 2017 Mar 01; 119(5):753-759.
Score: 0.097
-
Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design. Acad Emerg Med. 2016 11; 23(11):1280-1286.
Score: 0.096
-
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism? Clin Appl Thromb Hemost. 2017 Oct; 23(7):830-837.
Score: 0.094
-
Target-specific Oral Anticoagulants in the Emergency Department. J Emerg Med. 2016 Feb; 50(2):246-57.
Score: 0.090
-
Elevated international normalized ratio in the ED: clinical course and physician adherence to the published recommendations. Am J Emerg Med. 2005 Jan; 23(1):40-4.
Score: 0.042
-
Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis. Eur Heart J. 2024 Aug 21; 45(32):2933-2950.
Score: 0.041
-
Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Ann Emerg Med. 2020 10; 76(4):470-485.
Score: 0.030
-
The value of sPESI for risk stratification in patients with pulmonary embolism. J Thromb Thrombolysis. 2019 Jul; 48(1):149-157.
Score: 0.029
-
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018 Jun 07; 378(23):2191-2201.
Score: 0.027
-
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Curr Med Res Opin. 2017 09; 33(9):1697-1703.
Score: 0.025
-
Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clin Ther. 2017 Jul; 39(7):1426-1436.e2.
Score: 0.025
-
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).
Score: 0.024
-
Outcomes related to variation in hospital pulmonary embolus observation stay utilization. Hosp Pract (1995). 2016 Aug; 44(3):133-7.
Score: 0.023
-
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. Crit Pathw Cardiol. 2013 Sep; 12(3):107-15.
Score: 0.019